×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLS – sellas life sciences group, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/2
08:00 am
sls
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
Medium
Report
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
12/10
08:42 am
sls
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia [Yahoo! Finance]
Medium
Report
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia [Yahoo! Finance]
12/10
08:30 am
sls
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
Medium
Report
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
12/9
08:50 am
sls
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML [Yahoo! Finance]
Medium
Report
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML [Yahoo! Finance]
12/9
08:45 am
sls
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
Medium
Report
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
11/27
08:45 am
sls
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
Medium
Report
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
11/13
06:05 pm
sls
SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]
Low
Report
SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]
11/13
04:15 pm
sls
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/10
04:46 pm
sls
Form 8-K SELLAS Life Sciences For: Dec 10
High
Report
Form 8-K SELLAS Life Sciences For: Dec 10
12/5
05:06 pm
sls
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: Stergiou Angelos M.
Medium
Report
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: Stergiou Angelos M.
12/5
05:06 pm
sls
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: CICIC DRAGAN
Medium
Report
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: CICIC DRAGAN
12/5
05:05 pm
sls
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: Burns John Thomas
Medium
Report
Form 4 SELLAS Life Sciences For: Dec 04 Filed by: Burns John Thomas
11/13
04:18 pm
sls
Form 8-K SELLAS Life Sciences For: Nov 13
Medium
Report
Form 8-K SELLAS Life Sciences For: Nov 13
11/13
04:02 pm
sls
Form 10-Q SELLAS Life Sciences For: Sep 30
Low
Report
Form 10-Q SELLAS Life Sciences For: Sep 30
11/8
08:33 am
sls
Form SC 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G/A SELLAS Life Sciences Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC
10/4
04:06 pm
sls
Form 8-K SELLAS Life Sciences For: Oct 03
Low
Report
Form 8-K SELLAS Life Sciences For: Oct 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/2
Form 8-K SELLAS Life Sciences For: Jul 01
37.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
5/31 Form 8-K SELLAS Life Sciences For: May 31 10.3%
8/14 Form 8-K SELLAS Life Sciences For: Aug 14 7.5%
7/15 Form 8-K SELLAS Life Sciences For: Jul 12 6.8%
8/5 Form DEF 14A SELLAS Life Sciences For: Sep 10 4.5%
4/28 SELLAS Releases Annual Letter to Shareholders 4.1%
11/25 Form 8-K SELLAS Life Sciences For: Nov 25 3.1%
2/26 SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) 1.9%
1/17 Form SC 13G SELLAS Life Sciences Filed by: CVI Investments, Inc. 1.3%
3/16 Form 4 SELLAS Life Sciences For: Mar 12 Filed by: Burns John Thomas 1.1%
TOP News Decliners
6/14
Form EFFECT SELLAS Life Sciences
-55.6%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
11/6 SELLAS Announces Reverse Stock Split -27.8%
5/23 Form S-1 SELLAS Life Sciences -27.0%
7/9 Form 8-K SELLAS Life Sciences For: Jul 08 -19.5%
1/13 SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones -19.4%
11/14 Form 8-K SELLAS Life Sciences For: Nov 14 -18.3%
7/31 SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study -18.1%
7/9 Form 8-K SELLAS Life Sciences For: Jul 09 -15.3%
1/8 SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML) -12.9%
6/6 Form S-1/A SELLAS Life Sciences -10.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: